Skip to main content
Clinical and Applied Thrombosis/Hemostasis logoLink to Clinical and Applied Thrombosis/Hemostasis
. 2020 Oct 6;26:1076029620965327. doi: 10.1177/1076029620965327

Erratum to “A Meta-Analysis Evaluating the Incidence of Bleeding Events With Intravenous Defibrotide Treatment Outside the Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Setting”

PMCID: PMC7543152  PMID: 33021098

Tappe W, Aggarwal S, Topaloglu O, Iacobelli, M. A Meta-Analysis Evaluating the Incidence of Bleeding Events With Intravenous Defibrotide Treatment Outside the Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Setting.

Clinical and Applied Thrombosis/Hemostasis. 2020;26:1-9. DOI: https://doi.org/10.1177/1076029620935202

Due to a formatting error that occurred during the layout process, the reference numbers in the published versions of Figures 2 and 3 did not align with the authors/dates shown in the figures. The correct versions of Figures 2 and 3 are below:

graphic file with name 10.1177_1076029620965327-fig1.jpg

Figure 2.

Figure 2.

Bleeding rates for IV defibrotide (A) and controls regardless of route of administration (B). CI indicates confidence interval; ES, effect size; IV, intravenous.

Figure 3.

Figure 3.

Risk ratio of bleeding for IV formulation of defibrotide versus controls. bid indicates 2 times a day; CI, confidence interval; df, degrees of freedom; IV, intravenous; M-H, Mantel-Haenszel; post-op, postoperative; pre-op, preoperative; qid, 4 times a day.


Articles from Clinical and Applied Thrombosis/Hemostasis are provided here courtesy of SAGE Publications

RESOURCES